文献速递临床试验与 GCP基础与转化研究

海藻糖对伊朗颅脑创伤患者炎症标志物、氧化应激、临床症状及死亡率影响的随机对照试验方案

The effect of Trehalose on inflammatory markers, oxidative stress, clinical symptoms, and mortality in patients with head trauma in Iran: a double-blind, placebo-controlled, randomized clinical trial protocol.
PubMed 文献 · Trials · 2025-11-18

本研究为在伊朗伊斯法罕Al-Zahra医院开展的双盲随机对照试验方案,计划纳入80例18至65岁颅脑创伤患者,按个体随机分为两组各40例,分别接受每日10 g海藻糖或10 g麦芽糊精安慰剂治疗7天。主要结局包括炎症标志物、氧化应激标志物、临床评分、第28、60、90天死亡率及住院天数。

要点

  • 该方案评估每日10 g海藻糖对颅脑创伤患者炎症、氧化应激、临床结局及死亡率的影响。
  • 计划纳入80例18至65岁颅脑创伤患者,随机分为海藻糖组与麦芽糊精安慰剂组各40例。
  • 主要结局包括CRP、ESR、IL-6、TAC、SOD、MDA、SOFA、APACHE II、NUTRIC评分、死亡率及住院天数。

核心结论

  • 鉴于临床前颅脑创伤模型中海藻糖的抗炎和抗氧化作用,补充海藻糖可能改善颅脑创伤患者的结局。

研究设计与样本

  • 本研究为双盲随机对照试验方案,计划从伊朗伊斯法罕Al-Zahra医院招募80例18至65岁颅脑创伤患者,按个体随机分为两组各40例。

主要发现

  • 干预组每日接受10 g海藻糖,安慰剂组每日接受10 g麦芽糊精,疗程均为7天。
  • 主要结局包括炎症标志物(C反应蛋白、红细胞沉降率、白细胞介素6)、氧化应激标志物(总抗氧化能力、超氧化物歧化酶、丙二醛)、临床评分(序贯器官衰竭评估、急性生理与慢性健康评估II、危重症营养风险评分)、第28、60、90天死亡率及住院天数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The occurrence of traumatic brain injury (TBI) has been progressively increasing over the years, mainly due to factors such as driving accidents and falls. Globally, TBI is now considered a significant cause of death and disability, particularly among young adults. TBI leads to inflammation and oxidative stress, significantly contributing to increased mortality and long-term complications. The importance of early therapeutic interventions in patients with TBI has been highlighted in several studies. The impact of trehalose as an anti-inflammatory and antioxidant on TBI has been well documented in animal models; however, this effect remains inconclusive in humans. This study aims to assess the effects of trehalose on inflammatory markers, oxidative stress, clinical outcomes, and mortality in TBI patients. METHOD: In this double-blind randomized controlled trial, we will recruit 80 patients aged 18 to 65 years with TBI from Al-Zahra Hospital, Isfahan, Iran, and randomly allocate them at the individual level into two groups of 40. One group will receive 10 g of trehalose daily (intervention group), while the other will receive 10 g of maltodextrin (placebo group) for 7 days. Primary outcomes include inflammatory markers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin 6 (IL-6)), oxidative stress markers (total antioxidant capacity (TAC), superoxide dismutase (SOD), malondialdehyde (MDA)), clinical scores (sequential organ failure assessment (SOFA), Acute Physiology and Chronic Health Evaluation II (APACHE II), Nutrition Risk In Critically Ill (NUTRIC)), mortality (days 28, 60, 90), and hospital stay (day). DISCUSSION: Given the anti-inflammatory and antioxidant effects of trehalose observed in preclinical TBI models, its supplementation in patients with TBI may potentially improve the outcomes.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mohammadi MA, Bagherniya M, Alikiaii B, et al. The effect of Trehalose on inflammatory markers, oxidative stress, clinical symptoms, and mortality in patients with head trauma in Iran: a double-blind, placebo-controlled, randomized clinical trial protocol. Trials. 2025. PMID: 41254776. doi:10.1186/s13063-025-09220-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。